Cargando…

Ripretinib in gastrointestinal stromal tumor: the long-awaited step forward

Gastrointestinal stromal tumor (GIST) represents a paradigm for clinically effective targeted inhibition of oncogenic driver mutations in cancer. Five drugs are currently positioned as the standard of care for the treatment of advanced or metastatic GIST patients. This is the result of continuous, d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lostes-Bardaji, M. Julia, García-Illescas, David, Valverde, Claudia, Serrano, César
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7797597/ https://www.ncbi.nlm.nih.gov/pubmed/33473249 http://dx.doi.org/10.1177/1758835920986498

Ejemplares similares

Ripretinib for gastrointestinal stromal tumours
Publicado: (2021)

Ripretinib for the treatment of advanced gastrointestinal stromal tumor
por: Zalcberg, John R.
Publicado: (2021)

Emerging Data on the Safety and Efficacy of Ripretinib for the Treatment of Gastrointestinal Stromal Tumors
por: Thirasastr, Prapassorn, et al.
Publicado: (2023)

Cost-Effectiveness Analysis of Fourth- or Further-Line Ripretinib in Advanced Gastrointestinal Stromal Tumors
por: Liao, Weiting, et al.
Publicado: (2021)

Management of Patients With Advanced Gastrointestinal Stromal Tumor: Emphasis on Fourth-Line Treatment With Ripretinib
por: Brackert, Sandra, et al.
Publicado: (2023)

Compassionate Use of Ripretinib for Patients With Metastatic Gastrointestinal Stromal Tumors: Taiwan and Hong Kong Experience
por: Lin, Li-Ching, et al.
Publicado: (2022)

Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An Analysis of the INVICTUS Study
por: Zalcberg, John R., et al.
Publicado: (2021)

Corrigendum: Compassionate use of ripretinib for patients with metastatic gastrointestinal stromal tumors: Taiwan and Hong Kong experience
por: Lin, Li-Ching, et al.
Publicado: (2022)

Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous KIT/PDGFRA Mutations in the Phase III INVICTUS Study
por: Bauer, Sebastian, et al.
Publicado: (2021)

Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib
por: Janku, Filip, et al.
Publicado: (2020)

Efficacy and safety of ripretinib in Chinese patients with advanced gastrointestinal stromal tumors: a real-world, multicenter, observational study
por: Yang, Weili, et al.
Publicado: (2023)

Patient-reported outcomes in individuals with advanced gastrointestinal stromal tumor treated with ripretinib in the fourth-line setting: analysis from the phase 3 INVICTUS trial
por: Schöffski, Patrick, et al.
Publicado: (2022)

Ripretinib: First Approval
por: Dhillon, Sohita
Publicado: (2020)

Genotyping guided ripretinib directly after the progression of first-line imatinib therapy in advanced gastrointestinal stromal tumor: a case report
por: Huang, Shaoqing, et al.
Publicado: (2022)

Multi-disciplinary management of recurrent gastrointestinal stromal tumor harboring KIT exon 11 mutation with the switch-control kinase inhibitor ripretinib and surgery
por: Gouda, Mohamed A., et al.
Publicado: (2023)

Correction to: Ripretinib: First Approval
por: Dhillon, Sohita
Publicado: (2020)

Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial
por: Bauer, Sebastian, et al.
Publicado: (2022)

Ripretinib in combination with tyrosine kinase inhibitor as a late-line treatment option for refractory gastrointestinal stromal tumors: two case reports and literature review
por: Zhang, Yefan, et al.
Publicado: (2023)

Efficacy and Safety of Ripretinib in Chinese Patients with Advanced Gastrointestinal Stromal Tumors as a Fourth- or Later-Line Therapy: A Multicenter, Single-Arm, Open-Label Phase II Study
por: Li, Jian, et al.
Publicado: (2022)

Overcoming heterogenity in imatinib-resistant gastrointestinal stromal tumor
por: Serrano, César, et al.
Publicado: (2019)

Efficacy and safety of ripretinib in patients with KIT-altered metastatic melanoma
por: Janku, F., et al.
Publicado: (2022)

Clinical value of next generation sequencing of plasma cell-free DNA in gastrointestinal stromal tumors
por: Serrano, César, et al.
Publicado: (2020)

2023 GEIS Guidelines for gastrointestinal stromal tumors
por: Serrano, César, et al.
Publicado: (2023)

SEOM-GEIS clinical guideline for gastrointestinal stromal tumors (2022)
por: Serrano, César, et al.
Publicado: (2023)

Systemic mastocytosis, in the context of a deleterious germline SDHC variant, treated with ripretinib
por: Saheb Kashaf, Sara, et al.
Publicado: (2023)

Silencing of adaptor protein SH3BP2 reduces KIT/PDGFRA receptors expression and impairs gastrointestinal stromal tumors growth
por: Serrano‐Candelas, Eva, et al.
Publicado: (2018)

Long-Awaited Results from Long Island Study
por: Holzman, DC
Publicado: (2003)

A Long-Awaited Structure Is Rev-ealed
por: Hammarskjold, Marie-Louise, et al.
Publicado: (2011)

Clinical relevance of circulating molecules in cancer: focus on gastrointestinal stromal tumors
por: Ravegnini, Gloria, et al.
Publicado: (2019)

Awaiting the “catharsis”
por: Yfantopoulos, John
Publicado: (2020)

The Pharmacokinetic Effect of Itraconazole and Voriconazole on Ripretinib in Beagle Dogs by UPLC-MS/MS Technique
por: Wang, Hui-jun, et al.
Publicado: (2021)

Gastrointestinal stromal tumor
por: Stamatakos, Michael, et al.
Publicado: (2009)

Gastrointestinal stromal tumors
por: Beham, Alexander W., et al.
Publicado: (2011)

Succinate Dehydrogenase-Deficient Gastrointestinal Stromal Tumors: Small Steps Toward Personalized Medicine?
por: Ravegnini, Gloria, et al.
Publicado: (2019)

Meniscal substitution, a developing and long-awaited demand
por: Winkler, Philipp W., et al.
Publicado: (2020)

This is not the end: A long‐awaited update of the definition of pain
por: Andersen, Randi Dovland
Publicado: (2021)

A long-awaited taxogenomic investigation of the family Halomonadaceae
por: de la Haba, Rafael R., et al.
Publicado: (2023)

The Pharmacokinetic Effect of Itraconazole and Voriconazole on Ripretinib in Beagle Dogs by UPLC-MS/MS Technique [Corrigendum]
Publicado: (2023)

Gastrointestinal Stromal Tumor: Cause of Gastrointestinal Bleeding
por: Vilallonga, Ramon, et al.
Publicado: (2010)

Unresectable gastrointestinal stromal tumors
por: Menon, Prema, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_savfj4gk853rnt7apu7vi7m0lo